Trilostane in advanced breast cancer

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 17, 2006, Pages 2413-2419

  Puddefoot, John R ^a   Barker, Stewart ^a   Vinson, Gavin P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Allosteric modulator; Breast cancer; Selective estrogen receptor modulator; Trilostane

Indexed keywords

AMINOGLUTETHIMIDE; ANTIESTROGEN; AROMATASE INHIBITOR; DEXAMETHASONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID; GOSERELIN; GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; NONSTEROID ANTIINFLAMMATORY AGENT; TAMOXIFEN; TRILOSTANE;

ADD ON THERAPY; ALLOSTERISM; ARTICLE; BREAST CANCER; CANCER RELAPSE; CLINICAL TRIAL; CUSHING SYNDROME; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EROSIVE GASTRITIS; GASTRITIS; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEMATEMESIS; HORMONE DEFICIENCY; HORMONE INHIBITION; HUMAN; HYPERALDOSTERONISM; HYPOKALEMIA; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MELENA; META ANALYSIS; NAUSEA; NONHUMAN; ORAL PARESTHESIA; PATIENT COMPLIANCE; PEPTIC ULCER; POSTMENOPAUSE; PROSTATE CANCER; SINGLE DRUG DOSE; STOMACH PERFORATION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIHYDROTESTOSTERONE; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RATS;

EID: 33751585352     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.17.2413     Document Type: Article

References (50)

1. BEATSON GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet (1896) ii:104-107.
2. JENSEN EV, JACOBSEN HI: Basic guides to the mechanism of estrogen action. Recent Progress in Hormone Research (1962) 18:387-414.
3. COLE MP, JONES AC, TODD IDH: A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI146474. Br. J. Cancer (1971) 25:270-275.
4. BUZDAR AU, JONES SE, VOGEL CL: A Phase III trial comparing anastrozole (1 and 10 milligrams) a potent and selective aromatase inhibitor, with megestrol acetate in post menopausal women with advanced breast carcinoma. Arimidex study Group. Cancer (1997) 79:730-739
5. HOWELL A, DOWNEY S, ANDERSON E: New endocrine therapies for breast cancer. Eur. J. Cancer (1996) 32A:576-588.
6. JORDAN VC: Tamoxifen: a personal retrospective. The Lancet Oncol. (2000) 1:43-49.
7. NORMANNO N, DIMAIO M, DE MAIO E et al.: Mechanism of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine Related Cancer (2005) 12:721-747.
8. NEVEN P, VERGOTE I: Tamoxifen screening and new oestrogen receptor modulators. Baillieres Best Pract Res. Clin. Obstet. Gynaecol. (2001) 15:365-380.
9. O'REGAN RM, JORDAN VC: Tamoxifen to raloxifene and beyond. Semin. Oncol. (2001) 28:260-273.
10. ROBERTSON JFR: Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat. Rev. (2004) 30:695-706.
11. HARPER-WYNNE C, DOWSETT M: Recent advances in the clinical application of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. (2001) 76:179-186.
12. DODWELL D, WARDLEY A, JOHNSTON S: Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast J. (2006) Epub ahead of print.
13. POTTS GO, CREANGE JE, HARDING HR, SCHANE HP: Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids (1978) 32:257-267.
14. BEARDWELL CG, HINDLEY AC, WILKINSON PM, ST JOHN J, BU'LOCK D: Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. Clin. Endocrinol. (1985) 23:413-421.
15. RABE T, KIESEL L, KELLERMAN J, WEIDENHAMMER K, RUNNEBAUM B, POTTS GO: Inhibition of human placental progesterone synthesis and aromatase activity bysyntheric steroidogenic inhibitors in vitro. Fertil. Steril. (1983) 39:829-835.
16. TONETTI DA, JORDAN VC: The oestrogen receptor: a logical target for the prevention of breast cancer with antioestrogens. J. Mammary Gland Biol. Neoplasia (1999) 4:401-413
17. WITTLIFF JL: Steroid-hormone receptors in breast cancer. Cancer (1984) 53:630-643.
18. KUIPER GG, ENMARK E, PELTO-HUIKKO M, NILSSON M, GUSTAFSSON JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93: 5925-5930.
19. GUSTAFSSON JA: Estrogen receptor beta - a new dimension in estrogen mechanism of action. J. Endocrinol (1999) 163:379-383.
20. PUDDEFOOT JR, BARKER S, GLOVER HR, MALOUITRE SD, VINSON GP: Non-competitive steroid inhibition of oestrogen receptor functions. Int. J. Cancer. (2002) 101:17-22.
21. BARKER S: Antioestrogens in the treatment of breast cancer: current status and future directions. Curr. Opin. Investigational Drugs (2003) 4:652-657
22. BARKER S, MALOUITRE SD, GLOVER HR, PUDDEFOOT JR, VINSON GP: Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J. Steroid Biochem. Molecular Biol. (2006) In press.
23. BARKER S, CLOVER HR, MALOUITRE SDM, PUDDEFOOT JR, VINSON GP: Trilostane blocks actions of oestrogens through two pathways. Eur. J. Cancer (2003) 1(Suppl.):20.
24. HALL JM, MCDONNELL DP: The estrogen receptor beta-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 140:5566-5578.
25. BARDIN A, BOULLE N, LAZENNEC G, VIGNON F, PUJOL P: Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer (2004) 11:537-551.
26. ESSLIMANI-SAHLA M, SIMONY-LAFONTAINE J, KRAMAR A et al.: Estrogen receptor beta (ER β) level but not its ER β Cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res. (2004) 10:5769-5776.
27. ROBINSON DT, EARNSHAW RJ, MITCHELL R, POWLES P, ANDREWS RS, ROBERTSON WR: The bioavailability and metabolism of trilostane in normal subjects, a comparitive study using high pressure liquid chromatographic and quantitative cytochemical assays. J. Steroid Biochem. (1984) 21:601-605.
28. MCGEE JP, SHAW PN: The pharmacokinetics of trilostane and ketotrilostane in an interconverting system in the rat. Pharm. Res. (1992) 9:464-468.
29. POWLES P, ROBINSON DT, ANDREWS RS: Determination of trilostane and ketotrilostane in human plasma by high performance liquid chromatography. J. Chromatography (1984) 311:434-442.
30. BROWN RR, STROSHANE RM, BENZIGER DP: High performance liquid chromatographic assay for trilostane and its major metabolite, 17-ketotrilostane, in human plasma. J. Chromatography (1985) 339:440-444.
31. MURRAY R, PITT P: Effectiveness of adrenal blockade with trilostane after prior tamoxifen therapy in women with advanced breast cancer. J. Steroid Biochem. (1987) 28:1025-1030.
32. T'HOOFT-ANDRY M, FOCAN C, CLARYSSE A, MICHEL J, HEUSON JC, PARIDAENS R: Trilostane plus hydrocortisone in postmenopausal women with advanced breast cancer. A Phase II study of the Belgian Society of Medical Oncology. International Symposium on Hormonal Manipulation Of Cancer; Peptides, Growth Factors And New (Anti) Steroidal Agents. Rotterdam, Holland (1986) Abstr. 114.
33. BEARDWELL CG, HINDLEY AC, WLIKINSON PM, TODD ID, RIBEIRO GG, BU'LOCK D: Trilostane in the treatment of advanced breast cancer. Cancer Chemother. Pharmacol. (1983) 10:158-160.
34. THURLIMANN B, VARINI M, SENN HJ: Endocrine therapy with trilostane in pretreated advanced breast cancer. Tumor Diagnostik and Therapie (1990) 11:5-7.
35. WILLIAMS CJ, BARLEY V, BLACKLEDCE G, HUTCHEON A, KAYE S, SMITH D, KEEN C, WEBSTER DJT: Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treatment Reports (1987) 71:1197-1200.
36. HARVEY HA, SANTEN RJ, DEMERS LM, LIPTON A, WHITE-HERSHEY D, SHAFIK A: The separate and combined hormonal and clinical effects of trilostane and hydrocortisone in metastatic breast cancer. Breast Cancer Res. Treat. (1986) 8:82.
37. WILLIAMS CJ, BARLEY VL, BLACKLEDCE GR et al.: Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clinical Oncology (1995) 7:87-92.
38. ROSE C, MOURIDSEN HT, WILDIERS J, PARIDAENS R, SYLVESTER R, ROTMMENSZ N: Second line therapy in advanced breast cancer. A randomized phase II study, comparing aminoglutethimide plus hydrocortisone vs medroxyprogesterone acetate vs trilostane plus hydrocortisone vs hydrocortisone: an EORTC study. Eur. Organ. Res. Treat Cancer (1987) 18:89-97.
39. HAYWARD GL, RUBENS RD, CARBONE PP, HEUSON JC, KUMAOKA S, SEGALOFF A: Assessment of response to therapy in advanced breast cancer. Br. J. Cancer (1977) 35:292-296.
40. LEONARD RCF, BUNDRED N, CANNEY P et al.: Meta analysis of Trilostane (Modrenal®) advanced post-menopausal breast cancer evaluated by prior exposure to anti-oestrogen treatments. Eur. J. Cancer (2003) 1(Suppl):47.
41. KOMANICKY P, SPARK RF, MELBY JC: Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metab. (1978) 47:1042-1051.
42. DEWIS P, ANDERSON C, BUL'LOCK DE, EARNSHAW R, KELLY WF: Experience with trilostane in the treatment of Cushing's syndrome. Clin. Endocr. (1983) 18:533-540.
43. SEMPLE CG, BEASTALL GH, GRAY CE, THOMSON JA: Trilostane in the management of Cushing's syndrome. Acta Endocr. (1983) 102:107-110.
44. BRADDOCK JA, CHURCH DB, ROBERTSON ID, WATSON AD: Trilostane treatment in dogs with pituitary dependent hyperadrenocorticism. Aust. Vet. J. (2003) 81:600-607.
45. SIEBER-RUCKSTUHL N, BORETTI FS, WENGER M, MASER-GLUTH C, REUSCH CE: Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Domestic Animal Endocrinology (2006) 31:63-75.
46. NEIGER R, RAMSAY J, O'CONNOR J, HURLEY KJ, MOONEY CT: Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet. Rec. (2002) 150:799-804.
47. NAKADA T, KAZAM T, KOIKE H, YOSHIKAWA M, ISHIKAWA S, KATAYAMA T: Primary aldosteronism treated by trilostane (3-β-hydroxysteroid dehydrogenase inhibitor). Urology (1985) 25:207-214
48. NOMURA K, DEMURA H, HORIBA N, SHIZUME K: Long-term treatment of idiopathic hyperaldosteronism using trilostane. Acta Endocrinol. (1986) 113:104-110.
49. MALOUITRE SD, BARKER S, PUDDEFOOT JR JALILI J, GLOVER HR, VINSON GP: Regulation of hepatic steroid receptors and enzymes by the 3P-hydroxysteroid dehydrogenase inhibitor trilostane. J. Steroid Biochem. Molecular Biol. (2006) in press.
50. TORLAKOVIC E, LILLEBY W, BERNER A, TORLAKOVIC C, CHIBBAR R, FURRE T, FOSSÅ SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int. J. Cancer (2005) 117:381-386.